Publicaciones en colaboración con investigadores/as de Complejo Hospitalario de Toledo (29)

2024

  1. T-cell immune profile in blood of systemic mastocytosis: Association with disease features

    Allergy: European Journal of Allergy and Clinical Immunology

2021

  1. COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, Núm. 5, pp. 2083-2086

2020

  1. Identification and immunophenotypic characterization of normal and pathological mast cells

    Methods in Molecular Biology (Humana Press Inc.), pp. 331-353

2019

  1. Bone marrow mast cell antibody-targetable cell surface protein expression profiles in systemic mastocytosis

    International Journal of Molecular Sciences, Vol. 20, Núm. 3

2018

  1. Characterization of CD34 + hematopoietic cells in systemic mastocytosis: Potential role in disease dissemination

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 73, Núm. 6, pp. 1294-1304

  2. Impact of somatic and germline mutations on the outcome of systemic mastocytosis

    Blood Advances, Vol. 2, Núm. 21, pp. 2814-2828

2017

  1. Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature

    Oncotarget, Vol. 8, Núm. 40, pp. 68950-68963

2016

  1. Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis

    Journal of Allergy and Clinical Immunology, Vol. 137, Núm. 1, pp. 168-178.e1

  2. Diagnosis and classification of mastocytosis in non-specialized versus reference centres: A Spanish Network on Mastocytosis (REMA) study on 122 patients

    British Journal of Haematology, Vol. 172, Núm. 1, pp. 56-63

  3. Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression

    Leukemia, Vol. 30, Núm. 1, pp. 124-130

  4. KIT D816V-mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression

    Blood, Vol. 127, Núm. 6, pp. 761-768

2015

  1. Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: Diagnostic implications

    Modern Pathology, Vol. 28, Núm. 8, pp. 1138-1149

  2. Ex vivo identification and characterization of a population of CD13high CD105+ CD45- mesenchymal stem cells in human bone marrow

    Stem Cell Research and Therapy, Vol. 6, Núm. 1

  3. The immunophenotype of mast cells and its utility in the diagnostic work-up of systemic mastocytosis

    Journal of Leukocyte Biology, Vol. 97, Núm. 1, pp. 49-59

2014

  1. Flow cytometry in mastocytosis: Utility as a diagnostic and prognostic tool

    Immunology and Allergy Clinics of North America, Vol. 34, Núm. 2, pp. 297-313

  2. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM

    Journal of Allergy and Clinical Immunology, Vol. 133, Núm. 2

2013

  1. CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis

    Histopathology, Vol. 63, Núm. 6, pp. 780-787

  2. Flow cytometry criteria for systemic mastocytosis: Bone marrow mast cell counts do not always count

    American Journal of Clinical Pathology

  3. Gene expression profile of highly purified bone marrow mast cells in systemic mastocytosis

    Journal of Allergy and Clinical Immunology, Vol. 131, Núm. 4

  4. Serum Tryptase Monitoring in Indolent Systemic Mastocytosis: Association with Disease Features and Patient Outcome

    PLoS ONE, Vol. 8, Núm. 10